Bayer
100 Bayer Road
Whippany
New Jersey
07981
United States
Tel: 1-877-229-3727
Website: http://www.career.bayer.us/
Email: careersus@bayer.com
About Bayer
It all starts with a friendship between two men, plenty of natural curiosity and two kitchen stoves. Businessman Friedrich Bayer and dyer Johann Friedrich Weskott use these to conduct experiments and eventually discover how to make the dye fuchsine.
On August 1, 1863, they found the "Friedr. Bayer et. comp." company in Wuppertal-Barmen, a 19th century startup with tremendous potential.
Bayer is a Life Science company with a more than 150-year history and core competencies in the areas of health care and agriculture. With our innovative products, we are contributing to finding solutions to some of the major challenges of our time.
Our goal is to create value for our customers, stockholders and employees, while also strengthening the company’s earning power. We are committed to operating sustainably and addressing our social and ethical responsibilities. Employees with a passion for innovation enjoy excellent development opportunities at Bayer.
All this goes to make up our purpose: Science for a better life.
Passion to innovate | Power to change
447 articles with Bayer
-
A federal investigation is underway into whether or not the nursing and other medical services provided by some pharmaceutical companies to doctor’s offices actually violate the law due to serving an illegal commercial service.
-
Compugen Announces Clinical Milestone Payment in Cancer Immunotherapy Collaboration With Bayer Following Dosing of First Patient in BAY 1905254 Phase 1 Trial
9/20/2018
Compugen entitled to $7.8 million milestone payment
-
Shares of OncoMed Pharmaceuticals are falling this morning after the company announced that Celgene has walked away from a deal to license the company’s bispecific antibody navicixizumab.
-
Bayer Animal Health and NeuroCycle Therapeutics sign global license agreement
9/12/2018
Bayer to strengthen its portfolio of products for companion animals with new allergy treatment options derived from NeuroCycle Therapeutics
-
TissUse establishes a liver-endocrine tissues multi-organ model for risk assessment with Bayer
9/10/2018
TissUse has signed a collaboration agreement with Bayer to develop a highly innovative liver-endocrine tissues assay using TissUse’s Multi-Organ-Chip (MOC) technology.
-
Bayer Receives FDA Approval for Jivi®, New Hemophilia A Treatment With Step-Wise Prophylaxis Dosing
8/31/2018
Jivi's extended half-life allows for twice-weekly initial dosing and may be adjusted to every five days and further individually adjusted to less or more frequent dosing(1)
-
Bayer Receives FDA Approval for Jivi®, New Hemophilia A Treatment With Step-Wise Prophylaxis Dosing Regimen
8/30/2018
Jivi's extended half-life allows for twice-weekly initial dosing and may be adjusted to every five days and further individually adjusted to less or more frequent dosing(1)
-
Hemophilia A patients have another treatment option. This morning the U.S. Food and Drug Administration gave the nod to Bayer AG’s new treatment, Jivi (BAY94-9027).
-
Integra Connect Becomes CancerLinQ® Platform’s First Certified Electronic Health Record
8/28/2018
CancerLinQ LLC announced today that Integra Connect’s EHR Solution for Oncology has been recognized as the first CancerLinQ® Certified Electronic Health Record (EHR) System.
-
Janssen Pharmaceutical and Bayer saw the good, the bad and the potential for ugly this week with their blockbuster blood-thinner Xarelto (rivaroxaban). The drug gained approval for a new indication in Europe, failed a late-stage trial and is staring down the barrel of patent loss in 2023 while ba...
-
Evotec AG and Haplogen GmbH have been long-term collaboration partners. The companies announced that Haplogen will enter into a multi-year drug discovery and development deal with Bayer AG to focus on pulmonary diseases like chronic obstructive pulmonary disease (COPD).
-
Almirall, headquartered in Barcelona, Spain, announced it is buying five dermatology products from Allergan. Those include Aczone (dapsone), Tazorac (tazarotene), Azelex (azelaic acid), Cordran Tape (fludroxycortide) and Seysara (sarecycline).
-
Ultragenyx Reports Second Quarter 2018 Financial Results and Corporate Update
8/2/2018
Ultragenyx Pharmaceutical Inc.(NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the quarter ended June 30, 2018.
-
Bayer reaffirms safety profile of Essure
7/27/2018
Women with Essure who have questions should consult their healthcare providers and be cautious about relying upon misinformation online
-
Bayer Fact Checks Netflix's The Bleeding Edge
7/27/2018
Bayer today released a Fact Check of The Bleeding Edge, which premieres on Netflix on July 27, devotes significant time to Essure, the only FDA-approved non-incisional form of permanent birth control, and is now the subject of media coverage by The New York Times, CBS News, and others.
-
Bayer to voluntarily discontinue U.S. sales of Essure at end of 2018 for business reasons
7/20/2018
The safety and efficacy of Essure have not changed [20-July-2018] WHIPPANY, N.J., July 20, 2018 /PRNewswire/ -- Bayer has made a business decision to voluntarily discontinue sales and distribution of the Essure ® System for Permanent Birth Control in the United States after December 31, 2018. This decision is based on a decline in U.S. sales of Essure
-
Statement from FDA Commissioner Scott Gottlieb, M.D., on manufacturer announcement to halt Essure sales in the U.S.; agency's continued commitment to postmarket review of Essure and keeping women informed
7/20/2018
The U.S. Food and Drug Administration was notified by Bayer that the Essure permanent birth control device will no longer be sold or distributed after December 31, 2018.
-
Recent studies in early diagnostics underline just how much focus medical technology companies are making on developing different modalities for very early cancer diagnosis. Here are just some recent examples.
-
It’s hard to believe 2018 is half over. There have been plenty of interesting and important stories in the biopharma space this year. Here’s a look at our top 10 stories so far, counting down from 10 to the number one story.
-
EVOTEC CONFIRM CLOSING OF TRANSACTION WITH SANOFI TO ACCELERATE INFECTIOUS DISEASE RESEARCH AND DEVELOPMENT
7/3/2018
Evotec AG today announced that the strategic transaction to integrate Sanofi's infectious disease unit including licensing-in the majority of Sanofi's infectious disease research portfolio, has been successfully closed with effect from 01 July 2018.